Spectrum Pharmaceuticals, Inc.  

(Public, NASDAQ:SPPI)   Watch this stock  
Find more results for SPPI
7.05
-0.05 (-0.70%)
Jul 25 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.95 - 7.16
52 week 6.36 - 10.32
Open 7.06
Vol / Avg. 655,097.00/1.27M
Mkt cap 462.83M
P/E     -
Div/yield 0.15
EPS -1.34
Shares 65.65M
Beta 1.74
Inst. own 67%
Aug 4, 2014
Q2 2014 Spectrum Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Jun 27, 2014
Spectrum Pharmaceuticals Inc Annual Shareholder Meeting
Jun 3, 2014
Spectrum Pharmaceuticals Inc at Jefferies Global Healthcare Conference
May 20, 2014
Spectrum Pharmaceuticals Inc at UBS Global Healthcare Conference
May 13, 2014
Spectrum Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 8, 2014
Q1 2014 Spectrum Pharmaceuticals Inc Earnings Conference Call - Webcast
May 8, 2014
Q1 2014 Spectrum Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -68.89% -39.87%
Operating margin -60.85% -24.89%
EBITD margin - -9.17%
Return on average assets -22.76% -12.38%
Return on average equity -40.52% -21.80%
Employees 226 -
CDP Score - -

Address

SUITE 240, 11500 S. EASTERN AVE.,
HENDERSON, NV 89052
United States - Map
+1-702-8356300 (Phone)
+1-702-2607405 (Fax)

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Spectrum Pharmaceuticals, Inc. (Spectrum) is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology. In the United States, the Company markets three oncology drugs, FUSILEV, FOLOTYN and ZEVALIN and also markets ZEVALIN outside of the United States, it has two drugs, apaziquone and belinostat, in late stage development along with a diversified pipeline of drug candidates.Apaziquone is studied in two Phase III clinical trials for non-muscle invasive bladder cancer, or NMIBC, and is under strategic collaborations with Nippon Kayaku Co. Ltd.(Nippon Kayaku), and Handok Pharmaceuticals Co. Ltd. (Handok). Belinostat, is being studied in multiple indications including a Phase II registrational trial for relapsed or refractory peripheral T-cell lymphoma (PTCL), under a strategic collaboration with TopoTarget A/S (TopoTarget). On September 5, 2012, it acquired Allos Therapeutics, Inc.

Officers and directors

Rajesh C. Shrotriya M.D. Chairman of the Board, Chief Executive Officer
Age: 70
Bio & Compensation  - Reuters
Joseph Turgeon President, Chief Operating Officer
Age: 56
Bio & Compensation  - Reuters
Kurt A. Gustafson Chief Financial Officer, Executive Vice President
Age: 46
Bio & Compensation  - Reuters
Brett L. Scott CPA Senior Vice President - Finance
Age: 62
Bio & Compensation  - Reuters
Lee F. Allen M.D. Ph.D. Senior Vice President, Chief Medical Officer
Age: 62
Bio & Compensation  - Reuters
Gilles R. Gagnon Director
Age: 60
Bio & Compensation  - Reuters
Luigi Lenaz M.D. Director
Age: 73
Bio & Compensation  - Reuters
Raymond Wayne Cohen Independent Director
Bio & Compensation  - Reuters
Stuart M. Krassner Independent Director
Age: 78
Bio & Compensation  - Reuters
Anthony E. Maida III Ph.D. Independent Director
Age: 62
Bio & Compensation  - Reuters